3-Bromo-8-chloro-[1,2,4]triazolo[4,3-a]pyrazine

Catalog No.: 
ACRTIA784
CAS No.: 
1936576-27-0
Molecular Formula: 
C5H2BrClN4
Molecular Weight: 
233.46
3-Bromo-8-chloro-[1,2,4]triazolo[4,3-a]pyrazine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg98%$456.00InquiryInquiry
250mg98%$884.00InquiryInquiry
1g98%$3465.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name3-Bromo-8-chloro-[1,2,4]triazolo[4,3-a]pyrazine
IUPAC Name3-bromo-8-chloro-[1,2,4]triazolo[4,3-a]pyrazine
MDL No.MFCD28368711
Molecular FormulaC5H2BrClN4
Molecular Weight233.46
SMILESClC1=NC=CN2C1=NN=C2Br
InChI KeyGCIVILJIVWOENV-UHFFFAOYSA-N
Synonym3-Bromo-8-chloro-[1,2,4]triazolo[4,3-a]pyrazine;1,2,4-Triazolo[4,3-a]pyrazine, 3-bromo-8-chloro-
CAS No.1936576-27-0

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Synthetic Route by SureRoute

1. ACRTIA784 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACRTIA784 route product structure diagram
    ACRTIA7841936576-27-0
Inquiry

2. ACRTIA784 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACRTIA784 route product structure diagram
    ACRTIA7841936576-27-0
Inquiry

3. ACRTIA784 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACRTIA784 route product structure diagram
    ACRTIA7841936576-27-0
Inquiry

Comments (0)